# API market entering critical phase of evolution

**Dr Sanjay Agrawal**

THE Active Pharmaceutical Ingredients (API) market in South East Asia is entering a critical phase of evolution. Once viewed primarily as a consumer market for finished pharmaceutical products, the region is now positioning itself as an emerging hub for API sourcing, manufacturing scale-up, and contract development and manufacturing (CDMO) services. This transition is driven by global supply-chain realignments, growing regional healthcare demand, and increasing interest from multinational pharmaceutical companies seeking diversification beyond traditional manufacturing centres.

Global demand for APIs continues to rise, supported by ageing populations, the increasing prevalence of chronic diseases, and sustained growth in generic and specialty medicines. Within this broader trend, Asia-Pacific remains one of the fastest-growing pharmaceutical regions. South East Asia, in particular, stands at an inflection point - offering structural advantages such as strategic geography, expanding industrial capacity, and supportive policy signals, while still grappling with gaps in scale, capability, and integration.

**Market dynamics**

APIs form the backbone of pharmaceutical manufacturing, and demand in South East Asia is being driven from both domestic and international fronts. On the domestic side, expanding healthcare access, demographic shifts, and rising disease burdens are increasing the need for affordable generics and selected specialty drugs. On the global side, pharmaceutical companies are actively re-evaluating supply-chain dependencies following pandemic-era disruptions and geopolitical uncertainties. This dual demand has created a multi-year growth runway for API investments across the region.

Despite this momentum, South East Asia does not yet match the scale or maturity of established API manufacturing powerhouses such as India and China. The regional ecosystem remains fragmented, characterised by small- and medium-sized manufacturers, a limited number of large-scale producers, and a growing pool of CDMOs aiming to capture outsourced synthesis and manufacturing opportunities. Chemical API activity is primarily concentrated in Indonesia, Vietnam, Thailand, and Malaysia, while Singapore is carving out a distinct role as a centre for high-value biologics, innovation partnerships, and advanced manufacturing services.

**Supply-chain realities**

China continues to play a dominant role in global API and intermediate supply chains, particularly for commodity and high-volume products. South East Asian manufacturers, like many of their global counterparts, remain heavily reliant on Chinese intermediates. This dependence introduces vulnerabilities, including exposure to price volatility, logistical disruptions, and upstream policy changes.

At the same time, this reliance presents a strategic opportunity.

Pharmaceutical buyers are increasingly prioritising supply-chain resilience and geographic diversification, creating openings for alternative manufacturing locations. While India has moved aggressively to capitalise on this shift through policy incentives and capacity expansion, South East Asian producers can leverage the same trend by positioning themselves as complementary rather than competing suppliers - offering flexibility, risk diversification, and regional proximity.

**Regulatory landscape**

Regulation remains one of the most influential non-market factors shaping the API industry in South East Asia. ASEAN regulators have made notable progress toward harmonisation through common frameworks and collaborative initiatives, but national regulatory differences persist. For manufacturers, this translates into a dual requirement: adherence to international Good Manufacturing Practice (GMP) standards and the ability to validate processes across multiple regulatory jurisdictions.

Encouragingly, regulators across the region are increasingly supportive of regional standards, inspector training programmes, and reliance models. However, implementing consistent compliance across a diverse supplier base remains a challenge. Manufacturers that invest early in robust quality systems, transparent data practices, and validation-ready operations are better positioned to convert regulatory alignment into a competitive advantage. In practice, regulatory maturity is increasingly becoming a commercial differentiator rather than a procedural obligation.

**Opportunities**

The strongest growth opportunities in South East Asia's API market lie in targeted niches rather than high-volume commodity production. CDMO services for mid-complexity APIs and specialty synthesis are particularly attractive, as global pharmaceutical companies seek reliable partners capable of meeting quality, confidentiality, and scalability requirements.

Green chemistry and continuous manufacturing offer additional avenues for differentiation. Reduced waste, lower energy consumption, and predictable scale-up are becoming critical selection criteria for buyers, driven by both cost considerations and sustainability expectations. Advanced manufacturing approaches not only improve operational efficiency but also align with evolving regulatory and environmental standards.

Biologics APIs and peptide synthesis represent another high-value segment. Although technically demanding and capital-intensive, these areas offer higher margins and long-term strategic relevance. Select facilities in Singapore, Thailand, and Malaysia are already building capabilities in this direction, supported by skilled talent pools and stronger innovation ecosystems.

**Challenges**

Despite its promise, the South East Asian API market faces significant structural challenges. API manufacturing requires experienced process chemists, sophisticated quality systems, and substantial capital investment in GMP-compliant infrastructure. Many regional firms struggle with talent shortages, extended approval timelines for capital projects, and limitations in utilities and industrial support systems.

Feedstock availability and price volatility for critical intermediates remain persistent concerns, particularly for manufacturers operating on thin margins. Additionally, the region must contend with illicit, industrial-scale production of controlled substances in certain areas, which complicates enforcement priorities and risks reputational spillover for legitimate manufacturers. Addressing these issues requires coordinated action involving policy clarity, regulatory enforcement, and industry self-regulation to preserve trust and market credibility.

**Strategic playbook**

A pragmatic strategy is essential for stakeholders aiming to succeed in South East Asia's evolving API landscape

- ***Early investment in GMP and validation***: Regulatory readiness should be embedded into project planning from the outset. Validation must be treated as a core component of development timelines rather than a downstream administrative step.
- ***Focus on niche differentiation***: Competing directly with established producers in commodity APIs is rarely sustainable. Mid-complexity APIs, specialty chemistries, and CDMO partnerships offer more viable growth paths.
- ***Adoption of modern manufacturing technologies***: Continuous processing, modular facilities, and green chemistry reduce variability, improve scalability, and enhance long-term competitiveness.
- ***Human capital development***: Partnerships with universities, technical institutes, and training organisations are critical for building a sustainable talent pipeline.
- ***Regional regulatory engagement***: Active participation in ASEAN harmonisation initiatives can accelerate approvals, enable mutual recognition, and reduce compliance friction.

**Role of governments**

Government support will be instrumental in shaping the next phase of API manufacturing in South East Asia. Policy measures such as targeted investment incentives, tax benefits for life-science infrastructure, fast-track approvals for utilities, and clear regulatory pathways can significantly lower entry barriers. Multilateral organisations, industry associations, and regional trade platforms also play a key role in facilitating knowledge exchange, partnership formation, and market access for emerging manufacturers.

**A long game, not a sprint**

The API market in South East Asia is steadily moving into strategic relevance, but its evolution will be measured over decades rather than quarters. While short-term gains are achievable, long-term success depends on sustained investment, capability building, and a deeply embedded culture of quality and compliance.

South East Asia is unlikely to displace established manufacturing giants in the near term, but it has the potential to become a preferred diversified sourcing destination for global pharmaceutical companies seeking resilience, regulatory confidence, and flexible manufacturing capacity. ◆

*(The author is a leading pharmaceutical consultant)*